login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Fluoroscopy times and radiation exposure during renal denervation compared to coronary procedures


Thursday, 15 Mar 2012 10:36

A retrospective analysis conducted in Germany shows that fluoroscopy times and radiation exposure in patients undergoing renal denervation are similar to those in patients undergoing routine diagnostic catheterisation with elective percutaneous coronary intervention but lower than in patients undergoing emergency intervention. The results were showed in a poster presentation at ISET in Miami, USA.


Ionising radiation carries an oncogenic risk which is linearly related to the dose and is closely related to procedural time. An estimation of the effective dose can be obtained from the measurements of the dose-area product, which is a measure of stochastic risk and a potential quality indicator,” the authors, led by Frank Himmel, Medizinische Klinik II, Universitätsklinikum Schleswig-Holstein, Lübeck, wrote.


The aim of the study was to assess fluoroscopy time, radiation exposure (dose area-product) and contrast dye consumption in patients undergoing renal denervation to treat medically resistant hypertension in comparison to diagnostic catheterisation and percutaneous coronary intervention.


A retrospective analysis of renal denervation therapy and adult cardiac percutaneous procedures (consecutive patients between January to May 2011 undergoing coronary angiography and ventriculography) was carried out to determine procedural characteristics and the dose-area product. The investigators identified four groups: group 1 (n=790, coronary angiography); group 2 (n=141, elective percutaneous coronary intervention in stable patients); group 3 (n=160, emergency percutaneous coronary intervention in acute coronary syndrome patients), group 4 (n=54, patients undergoing renal denervation). Dose-area product meter attached to the X-ray unit was used for the estimation of the radiation dose received by the patient during the procedures. In average renal denervation therapy consisted of 6–9 bilateral ablations spots.


The results showed that in the renal denervation group fluoroscopy time, dose-area product and contrast dye consumption were 10±1sec, 4878±456cGy cm2 and 141±6mL, respectively. In the elective percutaneous coronary intervention, fluoroscopy time was 11±1sec, dose-area product was 7457±421cGy cm2, and contrast dye consumption was 136±5mL. In emergency percutaneous coronary intervention patients, fluoroscopy time was 12±1sec, dose-area product was 9046±482cGy cm2, and contrast dye consumption was 213±6±5mL.


The authors concluded that the radiation dose varies substantially across different types of procedures and up to tenfold within the same procedure. “The enhanced knowledge of radiation dose might help the cardiologist to implement radiation sparing procedures minimising patient and operator radiation hazards in renal denervation,” they wrote.

 

 

Results (mean±standard error of the mean)

Body weight (kg)

Fluoroscopy time (sec)

Dose-area product (cGy cm2)

CDC (mL)

Group 1 (coronary angiography)

82±1

5±0.6

3514±99

99±1

Group 2 (elective PCI)

84±1

11±1*

7457±421*

136±5*

Group 3 (emergency PCI)

82±1

12±1*

9046±482*+

213±6*+

Group 4 (renal denervation)

92±3*

10±1*

4878±456*

141±6*

 

* p<0.05 vs. group 1, + p<0.05 vs. group 2




Add New Comment

Related Items


Most popular


Tuesday, 12 Aug 2014
Toshiba has announced that it will feature SURESubtraction Coronary at The European Society of Cardiology (ESC) congress (30 August–3 September, Barcelona, Spain). Toshiba Introduces SURESubtraction Coronary at ESC 2014

Friday, 22 Aug 2014
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAV... FDA 510(k) clearance for TAVI precision treatment planning application

Robotic PCI study reveals favourable results
Monday, 11 Aug 2014
The paper compared the outcomes of 40 patients that underwent PCI procedures at a single site in the PRECISE trial using the CorPath robotic system to the 80 consecutive patients who met the same ... Robotic PCI study reveals favourable results

Features


Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Transitioning from transfemoral to transradial: Why the transradial approach is here to stay
Thursday, 21 Aug 2014
William H Crowder believes that, despite some US interventional cardiologists’ reluctance to use the approach, the transradial approach will become standard of care for coronary catheterisation ... Transitioning from transfemoral to transradial: Why the transradial approach is here to stay

Profiles


Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions